CA2337571A1 - Antihistamine leukotriene combinations - Google Patents
Antihistamine leukotriene combinations Download PDFInfo
- Publication number
- CA2337571A1 CA2337571A1 CA002337571A CA2337571A CA2337571A1 CA 2337571 A1 CA2337571 A1 CA 2337571A1 CA 002337571 A CA002337571 A CA 002337571A CA 2337571 A CA2337571 A CA 2337571A CA 2337571 A1 CA2337571 A1 CA 2337571A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- antagonist
- composition
- leukotriene
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001387 anti-histamine Effects 0.000 title claims abstract 8
- 239000000739 antihistaminic agent Substances 0.000 title claims abstract 8
- -1 Antihistamine leukotriene Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 18
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 239000000203 mixture Substances 0.000 claims abstract 8
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims abstract 7
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims abstract 7
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract 7
- 239000005557 antagonist Substances 0.000 claims abstract 7
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims abstract 7
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract 5
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract 5
- 208000001319 vasomotor rhinitis Diseases 0.000 claims abstract 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims abstract 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims abstract 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims abstract 4
- 239000004606 Fillers/Extenders Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 239000002552 dosage form Substances 0.000 claims 5
- 238000011200 topical administration Methods 0.000 claims 3
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical group C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 2
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 claims 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical group CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims 2
- 229960004754 astemizole Drugs 0.000 claims 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004574 azelastine Drugs 0.000 claims 2
- 229960001803 cetirizine Drugs 0.000 claims 2
- 229960003592 fexofenadine Drugs 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 229960001120 levocabastine Drugs 0.000 claims 2
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims 2
- 229960001144 mizolastine Drugs 0.000 claims 2
- 229960005127 montelukast Drugs 0.000 claims 2
- 229960004583 pranlukast Drugs 0.000 claims 2
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims 2
- 229960004764 zafirlukast Drugs 0.000 claims 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical group C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 2
- 229960005332 zileuton Drugs 0.000 claims 2
- ZEYYDOLCHFETHQ-JOCHJYFZSA-N (2r)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical compound C1([C@@H](C(=O)O)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CCCC1 ZEYYDOLCHFETHQ-JOCHJYFZSA-N 0.000 claims 1
- CZIIGGQJILPHEU-HCHVXQBBSA-N 5-[(4r,5r)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-1-phenyl-5,6-dihydro-4h-cyclopenta[b]pyrrol-2-yl]pentanoic acid Chemical compound C([C@@H](O)[C@@H]1/C=C/[C@@H](O)CCCCC)C2=C1C=C(CCCCC(O)=O)N2C1=CC=CC=C1 CZIIGGQJILPHEU-HCHVXQBBSA-N 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- MDBPFVSVLGYVCQ-UHFFFAOYSA-N n-(4-fluorophenyl)-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)NC1=CC=C(F)C=C1 MDBPFVSVLGYVCQ-UHFFFAOYSA-N 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229950000204 piriprost Drugs 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a pharmaceutical composition for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis, which comprises (a) a nonsedating antihistamine or a pharmaceutically acceptable salt thereof, (b) a leukotriene D4 antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist, or a pharmaceutically acceptable salt thereof, and (c) one or more of a conventional pharmaceutical vehicle, extender, and excipient, and to its use for manufacturing a composition for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis.
Claims (19)
1. A pharmaceutical composition for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis, which comprises (a) a nonsedating antihistamine or a pharmaceutically acceptable salt thereof, (b) a leukotriene antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist, or a pharmaceutically acceptable salt thereof, and (c) one or more of a conventional pharmaceutical vehicle, extender, and excipient..
2. The pharmaceutical composition of claim 1, in which the nonsedating antihistamine is azelastine, levocabastine, cetirizine, fexofenadine, mizolastine, or astemizole..
3. The pharmaceutical composition of claim 1, wherein the leukotriene D4 antagonist is montelukast, zafirlukast or pranlukast.
4. The pharmaceutical composition of claim 1, wherein the 5-lipoxygenase inhibitor is zileuton, piriprost or AWD 23-115.
5. The pharmaceutical composition of claim 1, wherein the FLAP
antagonist is MK-591, MK-886 or Bay X 1005.
antagonist is MK-591, MK-886 or Bay X 1005.
6. The pharmaceutical composition of claims 1, wherein the concentration of the nonsedating antihistamine or salt is from 0.001 wt. % to 0.5 wt.
% based on the composition..
% based on the composition..
7. The pharmaceutical composition of claim 1, wherein the concentration of the leukotriene D4 antagonist or salt is from 0.01 wt.% to 5 wt.% based on the composition..
8. The pharmaceutical composition of claim 1, wherein the concentration of the 5-lipoxygenase inhibitor or salt is from 0.01 wt. % to 5 wt. % based on the composition..
9. The pharrmaceutical composition of claim 1, wherein the concentration of the FLAP antagonist.or salt is from 0.01 wt. % to 5 wt. %
based on the composition.
based on the composition.
10. The pharmaceutical composition of claim 1, wherein the concentration of said leukotriene D4 antagonist, 5-lipoxygenase inhibitor, or FLAP
antagonist, or a pharmaceutically acce ptable salt is from 0.01 wt. % to 5 wt. % based on the composition..
antagonist, or a pharmaceutically acce ptable salt is from 0.01 wt. % to 5 wt. % based on the composition..
11. The pharmaceutical composition of claim 10 in a dosage form for topical administration.
12. The pharmaceutical composition of claim 10 in a dosage form for oral administration.
13. The pharmaceutical composition of claim 11, wherein the dosage form for topical administration is a spray.
14. The pharmaceutical composition of claim 11, wherein the dosage form for topical administration is a nasal or eye drop.
15. A process for preparing the pharmaceutical composition of claim 1, which comprises combining said antihistamine and said component (b) with said component (c) and converting the resulting combination into a dosage form for administration.
16. Use of a composition of (a) a nonsedating antihistamine or a pharmaceutically acceptable salt thereof, (b) a leukotriene D4 antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist, or a pharmaceutically acceptable salt thereof, for preparing a pharmaceutical composition or pharmaceutical agents, for the simultaneous or sequential treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis.
17 17. Use of the pharmaceutical composition or ingredients of claim 16, wherein the nonsedating antihistamine is azelastine, levocabastine, cetirizine, fexofenadine, mizolastine, or astemizole.
18. Use of the pharmaceutical composdition or ingredients of claim 16, wherein the leukotriene D4 antagonist is zafirlukast, montelukast or pranlukast, the 5-lipoxygenase inhibitor is zileuton, piripost or AWD 23-115, and the FLAP
antagonist is MK-591, MK-886 or Bay 1005.
antagonist is MK-591, MK-886 or Bay 1005.
19. A pharmaceutical package containing the pharmaceutical composition of claim 1, further containing instructions for its use for the treatment of allergic rhinitis, vasomotor rhinitis, and allergic conjuntivitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002337571A CA2337571C (en) | 2001-02-20 | 2001-02-20 | Antihistamine leukotriene combinations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002337571A CA2337571C (en) | 2001-02-20 | 2001-02-20 | Antihistamine leukotriene combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2337571A1 true CA2337571A1 (en) | 2002-08-20 |
| CA2337571C CA2337571C (en) | 2009-12-22 |
Family
ID=4168402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002337571A Expired - Fee Related CA2337571C (en) | 2001-02-20 | 2001-02-20 | Antihistamine leukotriene combinations |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2337571C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005030331A1 (en) * | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
| WO2004087095A3 (en) * | 2003-03-31 | 2005-07-21 | Osmotica Costa Rica Sa | Osmotic controlled release device containing zafirlukast and an h1-antagonist |
| US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US8158362B2 (en) | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110496124A (en) * | 2019-04-10 | 2019-11-26 | 中山大学附属第五医院 | Compounds for the treatment of vascular malformations |
| WO2024126772A1 (en) | 2022-12-15 | 2024-06-20 | Noucor Health, S.A. | Pharmaceutical composition comprising rupatadine and montelukast |
-
2001
- 2001-02-20 CA CA002337571A patent/CA2337571C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| WO2004087095A3 (en) * | 2003-03-31 | 2005-07-21 | Osmotica Costa Rica Sa | Osmotic controlled release device containing zafirlukast and an h1-antagonist |
| WO2005030331A1 (en) * | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
| US8158362B2 (en) | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2337571C (en) | 2009-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001060407A3 (en) | Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis | |
| CA2460865A1 (en) | Quinoline derivatives as neuropeptide y antagonists | |
| HUP0101158A3 (en) | Use of glycogen phosphorylase inhibitors for the preparation of pharmaceutical compositions for the prophylactic treatment of type 2 diabetes mellitus | |
| IL191486A0 (en) | Piperidine derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for the treatment of tachykinis mediated conditions | |
| WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
| IL164108A (en) | Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders | |
| YU58103A (en) | Pharmaceutical dosage forms of epothilones for oral administration | |
| EP1461015A4 (en) | Compositions containing both sedative and non-sedative antihistamines | |
| WO2003087094A3 (en) | Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors | |
| CA2417106A1 (en) | Piperazine derivatives | |
| CA2472954A1 (en) | Aza-arylpiperazines | |
| MY141243A (en) | Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus | |
| HUP0200284A3 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them | |
| WO2007046868A3 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
| WO2002094774A3 (en) | Oxcarbazepine dosage forms | |
| WO2002100886A8 (en) | Pyrrolidin-2-one derivatives as inhibitors of factor xa | |
| HUP0104085A3 (en) | Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension | |
| WO2007038112A3 (en) | Combination of rosiglitazone and donepezil for improvement of cognitive function | |
| CA2337571A1 (en) | Antihistamine leukotriene combinations | |
| WO2003080125A3 (en) | Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors | |
| WO2005053727A3 (en) | Pharmaceutical compositions for bioactive peptide agents | |
| WO2002098850A3 (en) | Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors | |
| WO2002060435A8 (en) | Cryptotanshinone for preventing and alleviating alzheimer's disease | |
| WO2007067875A3 (en) | Pyridinyl sulfonamide modulators of chemokine receptors | |
| WO2005118579A3 (en) | Thiazole derivatives as chemokine receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180220 |